Tag: Merck & Co. Inc.
-
Merck’s $10.8 billion takeover of Prometheus gives it a foothold in immunology
[ad_1] Merck & Co.’s $10.8 billion acquisition of Prometheus Biosciences Inc., which it announced Sunday, is a strategic positive that will help the drug company diversify its portfolio and reduce the risk of an overreliance on its cancer drug Keytruda, analysts said Monday. San Diego, Calif.-based Prometheus RXDX, +69.34% is a clinical-stage biotechnology company focusing…
-
Moderna, Merck combo cancer-vaccine treatment shows ‘significant’ promise
[ad_1] A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing the risk of recurrence or death by 44%, the drug makers said Sunday. About 79% of melanoma patients in a 157-person trial who were treated with Moderna’s personalized mRNA-4157 (V940) therapy in combination with…